Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses

Huang, Xianggang; Xu, Jianqing; Qiu, Chao; Ren, Li; Liu, Lianxing; Wan, Yanmin; Zhang, Ning; Peng, Hong; Shao, Yiming

doi:10.1016/j.vaccine.2006.12.020

Cited by 30 publications

(21 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PEI/DNA complex can prolong DNA retention, and enhance the transfection of the target gene (25,26). Furthermore, PEI has previously been used in a heterologous prime-boost vaccination strategy (13).…”

Section: Discussionmentioning

confidence: 99%

An enhanced immune response against G250, induced by a heterologous DNA prime-protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

Sun

Liu

Ruan

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The heterologous DNA prime-protein boost vaccination approach has been widely applied as an immune treatment for carcinoma. However, inefficient delivery of DNA remains a major issue. In the present study, polyethyleneimine (PEI) was used as a DNA vector carrier to improve the transfection efficiency of the DNA vaccine and stimulate the humoral and cellular immunity against the renal carcinoma-associated antigen G250. A protein vaccine was included in the immunization strategy in order to produce a prime-boost effect. A DNA plasmid encoding an antigen G250 fragment was constructed and complexed with PEI. A protein vaccine against G250 was expressed in BL21 (DE3) Escherichia coli cells, by transformation with a pET28a(+)/C-G250 plasmid. The protein was purified using a nickel-nitriloacetic acid purification system. The in vitro transfection efficiency of the DNA vaccine was analyzed in HEK293 human endothelial kidney cells. The in vitro transfection efficiency in HEK293 cells was highest 48 h after transfection. Furthermore, mice were primed with 200 µg pVAX1/C-250 plasmid complexed with PEI, and boosted using 50 µg of purified C-G250 protein.In order to evaluate the immune response the antibody titer, splenocyte response, and interferon-γ levels from CD8+ T-cell splenocytes were analyzed using ELISA, lymphocyte proliferation or enzyme-linked immunosorbent spot assays. Firstly, the pVAX1/C-G250 plasmid was shown to be constructed successfully. As compared with the DNA group, the antibody titer, lymphocyte proliferation percentage, and cytokine production level induced by the DNA-PEI and DNA-PEI+C-G250 groups were significantly higher. Furthermore, the DNA-PEI+C-G250 group exhibited the strongest humoral and cellular response. Owing to the adjuvant effect of PEI, the pVAX1/C-G250-PEI prime plus C-G250 protein boost regimen could induce a strong immune response, and has been proved to be a potent vaccine candidate against renal cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

An enhanced immune response against G250, induced by a heterologous DNA prime-protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

Sun

Liu

Ruan

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The complexes formed by PEI and DNA can protect DNA from DNase degradation and facilitate the transfection of DNA, then release DNA from endosomes to cytosol. 24,25 The PEI/DNA complex could …”

Section: Discussionmentioning

confidence: 99%

“…25,26 Furthermore, PEI also exhibited some adjuvant activity. Garzon et al 27 examined the protective immune response against HIV-1 induced by the PEI/DNA complex, resulting in an improved cytokine production and antigen-specific CD8 + T-cell response.…”

mentioning

confidence: 98%

Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant

Li¹,

Jiang²,

Xu³

et al. 2013

IJN

View full text Add to dashboard Cite

Background:The heterologous deoxyribonucleic acid (DNA) prime-adenovirus (AdV) boost vaccination approach has been widely applied as a promising strategy against human immunodeficiency virus (HIV)-1. However, the problem of inefficient delivery and lack of specificity of DNA vaccine remains a major issue. In this paper, to improve the transfection of DNA vaccine and realize dendritic cell targeting, we used mannosylated polyethyleneimine (man-PEI) as a DNA vector carrier. Method: The DNA plasmid encoding antigen HIV gag fragment was constructed by polymerase chain reaction. Then the DNA plasmid was complexed with man-PEI. The in vitro transfection efficiency of man-PEI/DNA was analyzed on DC 2.4 cells. Mice were primed with 25 µg pVAX1-HIV gag plasmid complexed with man-PEI, 100 µg naked pVAX1-HIV gag plasmid, or empty pVAX1 vector and boosted by AdV encoding the same antigen. The antibody titer, CD4+ and CD8 + T-cell response, as well as interferon-γ and interleukin-4 levels in serum and in splenocytes culture were analyzed using flow cytometry or enzyme-linked immunosorbent assay to evaluate the immune response. To test a long-term effect of the vaccination regimen, CD8 + memory T-cell was also detected by flow cytometry. Results:The pVAX1-HIV gag was constructed successfully. The in vitro transfection efficiency in dendritic cells was significantly higher than naked DNA plasmid. Compared with 100 µg naked DNA/AdV group, the immunoglobulin G2a antibody titer, T-cell response percentage, and cytokine production level induced by man-PEI/DNA/AdV group were significantly higher at a lower DNA dose. Also, the man-PEI/DNA could stimulate a memory CD8 + T-cell response. Conclusion:Owing to the adjuvant effect of man-PEI, the man-PEI/pVAX1-HIV gag priming plus AdV boosting strategy proved to be a potent vaccine candidate against HIV, which could induce a stronger immune response with a lower DNA dose.

show abstract

“…Secretory IgA levels are generally very low, rarely exceeding values above 1,000 (38,39,48), and often can be determined only qualitatively (2,26,27,52). Immune responses against EHV-1 in horses, however, are characterized by high levels of EHV-specific IgA, identified as the predominant isotype upon natural EHV-1 infection (9).…”

Section: Discussionmentioning

confidence: 99%

Impact of ETIF Deletion on Safety and Immunogenicity of Equine Herpesvirus Type 1-Vectored Vaccines

Hofmann-Sieber

Wild

Fiedler

et al. 2010

J Virol

View full text Add to dashboard Cite

Heterologous gene transfer by viral vector systems is often limited by factors such as preexisting immunity, toxicity, low packaging capacity, or weak immunogenic potential. A novel viral vector system derived from equine herpesvirus type 1 (EHV-1) not only overcomes some of these obstacles but also promotes the robust expression of a delivered transgene and the induction of antigen-specific immune responses. Regarding an enhanced safety profile, we assessed the impact of the gene encoding the sole essential tegument protein, ETIF, on the replication and immunogenicity of recombinant EHVs. The deletion of ETIF severely attenuates replication in permissive RK13 cells and a human lung epithelial cell line but without influencing transgene expression. Whereas the intranasal administration of a recombinant luciferase EHV in BALB/c mice resulted in transgene expression in nasal cavities and lungs for 5 to 6 days, the ETIF deletion limited expression to 2 days and resulted in 30-fold-less luminescence. Attenuated replication was accompanied by a decreased capacity to induce CD8 ؉ T cells against a delivered HIV Gag transgene in BALB/c mice following repeated intranasal application. However, a single subcutaneous immunization with a gag DNA vaccine primed specific T cells for substantial expansion by two subsequent intranasal booster immunizations with either the gag recombinant ETIF mutant or the parental virus. In addition to inducing Gag-specific serum antibodies, this prime-boost strategy clearly outperformed three sequential immunizations with the parental or EHV-⌬ETIF virus or repeated DNA vaccination by inducing substantial specific secretory IgA (sIgA) titers.

show abstract

Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses

Cited by 30 publications

References 53 publications

An enhanced immune response against G250, induced by a heterologous DNA prime-protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

An enhanced immune response against G250, induced by a heterologous DNA prime-protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant

Impact of ETIF Deletion on Safety and Immunogenicity of Equine Herpesvirus Type 1-Vectored Vaccines

Contact Info

Product

Resources

About